Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIBOOST 2
NL-OMON59305Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib and cobicistat in non-small cell lung cancer (NSCLC) and EGFR-mutated non-small cell lung cancer (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Daily cumulative dose reduction while maintaining target osimertinib exposure and CNS disease control rate at 12 weeks. Started Jul 2024; status: recruiting.
02
Drugs
osimertinibcobicistat
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on NL-OMON59305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59305.